Clinical Trials Browser

Phase 1/2 × Completed × venetoclax × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02558816 2025-07-24

OAsIs

Phase 1/2 Completed

48 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02956382 2025-07-18

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Phase 1/2 Completed

24 enrolled 18 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Recurrence

NCT03583424 2025-05-14

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1/2 Completed

19 enrolled 12 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

103 enrolled

Plasma cell

Multiple Myeloma

NCT02611323 2023-10-10

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

133 enrolled 39 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

50 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01794520 2023-04-10

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

117 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

49 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT02287233 2022-08-29

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Phase 1/2 Completed

94 enrolled 37 charts

Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT02265731 2021-08-02

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Phase 1/2 Completed

38 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT02055820 2020-06-11

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Phase 1/2 Completed

267 enrolled 39 charts

Lymphoid

Lymphoma, Non-Hodgkin

Clinical Trials

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

OAsIs

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

MyDRUG

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL